Ocular surface squamous neoplasia in association with Crohn's disease

A 54-year-old male patient reported to the ophthalmic plastics and ocular oncology clinic of our institution (LV Prasad Eye Institute, Bhubaneswar, Odisha, India) in September, 2015, to seek a consultation for an ocular surface lesion in his right eye. Time domain anterior segment optical coherence...

Full description

Saved in:
Bibliographic Details
Published in:The lancet oncology 2020-11, Vol.21 (11), p.e538-e538
Main Authors: Tripathy, Devjyoti, Mittal, Ruchi
Format: Article
Language:English
Subjects:
Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
Azathioprine
Carcinoma, Squamous Cell - etiology
Carcinoma, Squamous Cell - pathology
Carcinoma, Squamous Cell - surgery
Crohn Disease - complications
Crohn Disease - diagnosis
Crohn Disease - drug therapy
Crohn's disease
Crohns disease
Epithelium
Eye Neoplasms - etiology
Eye Neoplasms - pathology
Eye Neoplasms - surgery
Glucocorticoids - therapeutic use
Humans
Inflammatory bowel disease
Keratin
Lesions
Male
Middle Aged
Oncology
Remission
Squamous cell carcinoma
Treatment Outcome
Tumors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 54-year-old male patient reported to the ophthalmic plastics and ocular oncology clinic of our institution (LV Prasad Eye Institute, Bhubaneswar, Odisha, India) in September, 2015, to seek a consultation for an ocular surface lesion in his right eye. Time domain anterior segment optical coherence tomography showed a hyper-reflective, irregularly thickened epithelium with intensely hyper-reflective surface keratin deposits, with areas of back shadowing corresponding to the thicker regions of the lesion, and a hypo-reflective clear space along the base of the lesion. At the most recent follow-up, 4 years and 5 months after surgical excision, he had no recurrence of the tumour and continued to have remission of symptoms of Crohn's disease on maintenance therapy with oral azathioprine (125 mg daily in two divided doses of 75 mg and 50 mg each, with monthly monitoring of haematological parameters).
ISSN:1470-2045
1474-5488
DOI:10.1016/S1470-2045(20)30277-1